Clinical trials: sponsored by Novartis Pharmaceuticals
Hypercholesterolemia
Study of Efficacy and Safety of Inclisiran in Asian Participants With Atherosclerotic Cardiovascular Disease (ASCVD) or ASCVD High Risk and Elevated Low Density Lipoprotein Cholesterol (LDL-C)
A multicenter study to evaluate safety and efficacy of inclisiran in Asian patients with ASCVD or ASCVD high risk and elevated LDL-C
- Trial name
- NCT04765657
- Testing
- inclisiran sodium
- Where
- 45 sites in China, Singapore and 2 more
- Volunteers
- 345 people
- Sponsor
- Novartis Pharmaceuticals
Hidradenitis Suppurativa (HS)
Short-term Treatment Satisfaction in Hidradenitis Suppurativa Patients Initiated on Cosentyx in Routine Clinical Practice in Saudi Arabia
This study aims to assess the treatment satisfaction of HS patients newly started on secukinumab in Saudi Arabia, in terms of patient reported convenience, perceived safety, perceived effectiveness and global treatment…
- Trial name
- ILLUMINATE-SA (NCT06785779)
- Testing
- Secukinmab
- Where
- 4 sites in Saudi Arabia
- Volunteers
- 77 people
- Sponsor
- Novartis Pharmaceuticals
Hypercholesterolaemia
LATAM LOWERS LDL-C
This is an open label, patient-level 1:1 randomized clinical trial in a multi-country study aiming to evaluate the real-world impact of inclisiran + Usual Care (UC) vs UC alone on LDL-C lowering, patient-reported outcomes, and…
- Trial name
- NCT06501443
- Testing
- Usual care, KJX839
- Where
- 11 sites in Argentina, Brazil
- Volunteers
- 520 people
- Sponsor
- Novartis Pharmaceuticals
Aplastic Anemia
Study Assessed the Safety and Efficacy of Eltrombopag in Chinese Refractory or Relapsed Severe Aplastic Anemia (SAA) Subjects.
This was a non-randomized, open-label, phase II study to assess the efficacy and safety of eltrombopag in Chinese subjects with refractory or relapsed severe aplastic anemia (SAA).
- Trial name
- NCT03988608
- Testing
- Eltrombopag
- Where
- 5 sites in China
- Volunteers
- 20 people
- Sponsor
- Novartis Pharmaceuticals
Relapsing Forms of Multiple Sclerosis
A Cross-sectional Study to Assess the Effectiveness and Safety of Ofatumumab (Kesimpta®) in Patients With Relapsing Multiple Sclerosis in the Spanish Clinical Practice
This was a non-interventional, cross-sectional, multicentric, and nationwide study, based on primary and secondary data collection.
- Trial name
- CRONOS-MS (NCT06251986)
- Testing
- ofatumumab
- Where
- 31 sites in Spain
- Volunteers
- 310 people
- Sponsor
- Novartis Pharmaceuticals
Moderate to Severe Chronic Plaque Psoriasis
A Real-world Study to Assess Safety and Effectiveness of Secukinumab in Pediatric Plaque Psoriasis Patients in China
This was a non-interventional, prospective, multi-center real world setting study, aiming to provide safety and effectiveness data in Chinese pediatric patients with moderate to severe plaque psoriasis treated with Cosentyx® for…
- Trial name
- NCT05388916
- Testing
- Cosentyx
- Where
- 7 sites in China
- Volunteers
- 42 people
- Sponsor
- Novartis Pharmaceuticals
Prostate Cancer
Study to Assess [177Lu]Lu-PSMA-R2 (AAA602) and [225Ac]Ac-PSMA-R2 (AAA802) in Participants With PSMA-positive HRLPC
The purpose of this trial is to learn more about the effects of AAA602 and AAA802 in men with prostate-specific membrane antigen (PSMA) positive high-risk localized prostate cancer (HRLPC) before surgery to remove the prostate…
- Trial name
- NeoPSMA (NCT06881823)
- Testing
- AAA602, AAA802, Gallium (68Ga) gozetotide
- Sponsor
- Novartis Pharmaceuticals
Multiple Myeloma (MM)
A Study of WVT078 in Patients With Multiple Myeloma (MM)
The design of a phase I, open-label, dose finding study was chosen in order to establish a safe and tolerated dose of single agent WVT078 alone and in combination with WHG626 in patients relapses and/or refractory Multiple…
- Trial name
- NCT04123418
- Testing
- WVT078, WHG626
- Where
- 12 sites in United States, Australia and 6 more
- Volunteers
- 56 people
- Sponsor
- Novartis Pharmaceuticals
BRAF V600 Colorectal Cancer
A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer
A phase Ib, open-label platform study of select drug combinations chosen in order to characterize safety and tolerability of each treatment arm tested and to identify recommended doses and regimens for future studies.
- Trial name
- NCT04294160
- Testing
- Dabrafenib, LTT462, Trametinib
- Where
- 18 sites in United States, Australia and 8 more
- Volunteers
- 122 people
- Sponsor
- Novartis Pharmaceuticals
Pancreatic Ductal Adenocarcinoma, Gastroesophageal Adenocarcinoma
A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors.
The purpose of the study is to test the safety and dosing of [177Lu]Lu-FF58, a radioligand therapy for patients with advanced or metastatic tumors that express proteins known as integrins: alpha-v beta-3 integrin (αvβ3) and…
- Conditions
- Pancreatic Ductal Adenocarcinoma, Gastroesophageal Adenocarcinoma, Glioblastoma Multiforme
- Trial name
- NCT05977322
- Testing
- 68Ga-FF58, 177Lu-FF58
- Where
- 5 sites in Israel, Netherlands and 2 more
- Volunteers
- 24 people
- Sponsor
- Novartis Pharmaceuticals
Moderate-to-severe Plaque Psoriasis
Secukinumab Drug Survival, Effectiveness and Tolerability in Pediatric Patients With Psoriasis
Multicenter, non-interventional, cohort study in pediatric patients with moderate to severe plaque-type psoriasis. Retrospective data collection is planned at patients' inclusion.
- Trial name
- SPARROW (NCT06142357)
- Testing
- Secukinumab
- Where
- 16 sites in Russia
- Volunteers
- 199 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
Survey Among Healthcare Professionals and MS Patients to Assess Their Understanding of RMP Materials
Survey to be completed independently by HCPs (neurologists treating patients with MS and MS specialist nurses) and patients/caregivers.
- Trial name
- NCT05301907
- Where
- Switzerland
- Volunteers
- 335 people
- Sponsor
- Novartis Pharmaceuticals
Progressive Supranuclear Palsy (PSP)
Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of NIO752 in Progressive Supranuclear Palsy
This is a phase 1, multi-center, double-blind, placebo-controlled, multiple dose escalation study with NIO752 in progressive supranuclear palsy (PSP) participants.
- Trial name
- NCT04539041
- Testing
- antisense oligonucleotide
- Where
- 12 sites in United States, Canada and 2 more
- Volunteers
- 59 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Myelogenous Leukemia in Chronic Phase
RWE,NIS,Prospective Study for the Effectiveness, Tolerability and Adherence of Asciminib in Saudi Arabia. (ASC4REAL)
This is a non-interventional, prospective, observational single arm study describing the real-world effectiveness, tolerability, adherence, Healthcare Resource Utilization (HCRU) and Patient-Reported Outcome (PRO) data of…
- Trial name
- ASC4REAL (NCT06684964)
- Testing
- asciminib
- Where
- 4 sites in Saudi Arabia
- Volunteers
- 40 people
- Sponsor
- Novartis Pharmaceuticals
IgA Nephropathy
Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients
The study is designed as a multicenter, randomized, double-blind, placebo controlled study to demonstrate the superiority of iptacopan (LNP023) at a dose of 200 mg b.i.d.
- Trial name
- APPLAUSE-IgAN (NCT04578834)
- Testing
- LNP023
- Where
- 177 sites in United States, Argentina and 33 more
- Volunteers
- 518 people
- Sponsor
- Novartis Pharmaceuticals
Primary Hypercholesterolemia or Mixed Dyslipidemia
Leqvio rPMS (Regulatory Post-Marketing Surveillance in Korea)
This non-interventional study is a mandatory regular Post Marketing Surveillance(rPMS) granted by the Korean health authorities, and is conducted to assess the effectiveness and safety of Leqvio® Pre-filled Syringe(inclisiran…
- Trial name
- NCT06770543
- Testing
- Inclisiran
- Where
- 4 sites in South Korea
- Volunteers
- 1,500 people
- Sponsor
- Novartis Pharmaceuticals
Somatostatin Receptor-positive Neuroendocrine Tumor
LUTATHERA Injection General Use Result Survey
This study was a multicenter observational study with a central registration system and all-case surveillance system without a control group.
- Trial name
- NCT05844332
- Testing
- LUTATHERA
- Where
- 46 sites in Japan
- Volunteers
- 347 people
- Sponsor
- Novartis Pharmaceuticals
Rotator Cuff Tendinopathy
Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy
The purpose of the present study was to assess the efficacy of secukinumab 300 mg s.c. (subcutaneous) compared to placebo, each in combination with standard of care, in improving signs, symptoms and physical function in…
- Trial name
- NCT05758415
- Testing
- Secukinumab
- Where
- 24 sites in United States, China and 4 more
- Volunteers
- 60 people
- Sponsor
- Novartis Pharmaceuticals
Melanoma
Compassionate Use Program to Access Trametinib and Dabrafenib for Patients With BRAF Mutation-positive Metastatic Melanoma
The purpose of this Cohort Treatment Plan is to allow access to trametinib (monotherapy or in combination) and dabrafenib (monotherapy or in combination) for eligible patients diagnosed with metastatic melanoma BRAF…
- Trial name
- NCT04489433
- Testing
- Dabrafenib and Trametinib, Dabrafenib, Trametinib
- Sponsor
- Novartis Pharmaceuticals
Hidradenitis Suppurativa (HS)
Managed Access Programs for AIN457, Secukinumab
The purpose of this registration is to list Managed Access Programs (MAPs) related to AIN457, secukinumab
- Trial name
- NCT05583604
- Testing
- secukinumab
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.